Access

You are not currently logged in.

Access your personal account or get JSTOR access through your library or other institution:

login

Log in to your personal account or through your institution.

Antibody to Polyribophosphate of Haemophilus influenzae Type B in Infants and Children: Effect of Immunization with Polyribophosphate

Porter Anderson, David H. Smith, David L. Ingram, Jeanette Wilkins, Paul F. Wehrle and Virgil M. Howie
The Journal of Infectious Diseases
Vol. 136, Supplement. Current Status and Prospects for Improved and New Bacterial Vaccines (Aug., 1977), pp. s57-s62
Published by: Oxford University Press
Stable URL: http://www.jstor.org/stable/30081786
Page Count: 6
  • Download ($42.00)
  • Subscribe ($19.50)
  • Cite this Item
Antibody to Polyribophosphate of Haemophilus influenzae Type B in Infants and Children: Effect of Immunization with Polyribophosphate
Preview not available

Abstract

Antibody to polyribophosphate, the capsular polysaccharide of Haemophilus influenzae type b, was measured in healthy ambulatory children by a radioactive antigen-binding assay. Titers fell from birth through nine months of age, then increased until six years, when they plateaued. Antibody activity was not correlated with the child's sex, ethnic status, or area of residence. Doses of 0.2-50 µg of polyribophosphate given as single or booster (loses had similar effects on antibody activity. Of 368 doses given to infants two to six months of age, 7% produced a significant antibody response; of 95 doses given to infants seven to 12 months old, 17% produced a response. The geometric mean titers of antibody resulting from immunization with polyribophosphate given at various times in relation to diphtheria-pertussistetanus vaccine did not differ significantly from one another or from titers observed in infants given only the latter vaccine. These data indicate that purified polyribophosphate will not provoke humoral immunity in young infants against H. influenzae type b and that it should no longer be considered as a candidate vaccine for this purpose.

Page Thumbnails

  • Thumbnail: Page 
S57
    S57
  • Thumbnail: Page 
S58
    S58
  • Thumbnail: Page 
S59
    S59
  • Thumbnail: Page 
S60
    S60
  • Thumbnail: Page 
S61
    S61
  • Thumbnail: Page 
S62
    S62